529 results about "Influenzavirus" patented technology

The invention belongs to the technical field of biology, and particularly relates to a group of paired monoclonal antibodies for resisting H9N2 subtype avian influenza viruses and a surface enhanced Raman spectroscopy rapid detection test strip established based on the antibodies. The paired monoclonal antibody comprises a labeled antibody 1E9 and a capture antibody 3C10 which are prepared by taking hemagglutinin protein of the H9N2 subtype avian influenza virus as antigens and can be specifically combined with the H9N2 subtype avian influenza virus. According to the invention, an SERS (Surface Enhanced Raman Scattering) probe Au-coated Pt-4ATP is used as a marker and is coupled with a labeled antibody 1E9 to prepare a labeled probe, and the labeled probe is paired with a capture antibody 3C10 to establish an SERS immunochromatography test strip. The test strip has a colorimetric and Raman dual interpretation mode, can be used for qualitative and quantitative detection, has the advantages of strong specificity, high sensitivity, good repeatability and stability and the like, is simple and rapid in clinical detection operation, and provides reliable technical support for on-site rapid screening of subtype viruses.

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a respiratory syncytial virus, a metapneumovirus, a human parainfluenza virus, or a combination thereof. The multisubunit nucleic acid encodes a multisubunit peptide.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting canine parainfluenza virus NP protein and application thereof. The combination is composed of monoclonal antibodies 5H10 and 1H7, 5H10 is used as a coating antibody, and 1H7 is used for colloidal gold labeling, so that efficient and specific sandwich detection of CPIV / NP antigen can be realized. The variable region CDR sequences of the heavy chains and light chains of the two antibodies are clear (SEQ ID NO. 1-12). The application also provides a rapid detection test strip based on the antibody combination, which can be used for on-site screening, early diagnosis and epidemiological monitoring of canine parainfluenza virus, solves the problem that existing detection technologies lack high-specificity recognition tools, and has a good application prospect.

The invention discloses a multi-subtype influenza A virus nucleic acid detection kit and a detection method, and relates to the technical field of medical detection.The kit comprises a group of reverse transcription RT-RPA amplification primer pairs used for amplifying influenza A virus M gene target sequences, the reverse transcription RT-RPA amplification primer pairs are designed for specific areas of subtypes H1N1, H2N2, H3N2, H5N1 and H7N9, and the reverse transcription RT-RPA amplification primer pairs are designed for specific areas of subtypes H1N1, H2N2, H3N2, H5N1 and H7N9; the crRNA library comprises a plurality of crRNA molecules which are respectively complementary with different conserved regions in the M gene target sequence and is used for guiding Cas12a protein to carry out specific recognition; a Cas12a protein reagent; the reporter molecule can be subjected to non-specific cleavage by the Cas12a protein; the enzyme preparation, the buffer solution and the nucleotide substrate are required by RT-RPA reaction. The invention aims to realize synchronous, rapid, high-sensitivity and high-specificity detection of various subtype influenza A viruses.

The invention provides a bovine parainfluenza virus type 3 QL3 strain, and the preservation number of the bovine parainfluenza virus type 3 QL3 strain is CGMCC No.46469. The invention also provides a bovine parainfluenza inactivated vaccine containing the bovine parainfluenza virus type 3 QL3 strain and purified F protein and HN protein of the QL3 strain. The novel bovine parainfluenza virus type 3 inactivated vaccine is obtained by optimizing the antigen components of the bovine parainfluenza virus type 3 inactivated vaccine, and high-level neutralizing antibodies can be generated after immunizing cattle; the safety of the vaccine is improved through process optimization. Safety and potency test results show that after the inactivated vaccine is used for immunizing cattle, no adverse reaction exists, and high-level neutralizing antibodies are generated. Results show that the immune effect of the bovine parainfluenza virus type 3 inactivated vaccine can be improved.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The invention discloses macromolecular antibacterial artificial leather and a preparation method thereof, and relates to the technical field of artificial leather preparation. The preparation method comprises the following steps: preparing zinc-loaded silicon dioxide with amino grafted on the surface and quaternized polyether polyurethane containing an epoxy group, mixing the zinc-loaded silicon dioxide and the quaternized polyether polyurethane to prepare antibacterial protection slurry, and bonding the zinc-loaded silicon dioxide and the quaternized polyether polyurethane through ring-opening reaction of the amino and the epoxy group during curing to form a cross-linked network, so as to obtain the antibacterial protection layer with antibacterial property, flexibility and wear resistance; zinc ions have an obvious inhibiting effect on bacteria such as gram-positive bacteria and gram-negative bacteria and fungi such as candida albicans, quaternary ammonium salt has an obvious inhibiting effect on influenza viruses, and the zinc ions and the quaternary ammonium salt have a synergistic effect, so that the antibacterial range of the artificial leather is wider, the inhibiting force on germs is stronger, and the antibacterial property of the artificial leather is further improved.

The invention provides an influenza vaccine adjuvant based on lentinan as well as a preparation method and application thereof. The active ingredient of the vaccine adjuvant is lentinan, the lentinan is extracted from fresh lentinus edodes through a water extraction and alcohol precipitation method, no additional chemical modification is needed, the vaccine adjuvant can be used for preparing the influenza virus vaccine, and the influenza virus vaccine at least contains one of three inactivated influenza virus antigens, namely H1N1 A, H3N2 A and Victoria B. The invention also provides a vaccine preparation and a preparation method thereof, the vaccine preparation comprises the vaccine adjuvant and an influenza virus vaccine, the content of lentinan in the vaccine preparation is 4 mg / mL, and the vaccine preparation has an immunological enhancement effect.

The invention provides application of high-concentration colloidal gold in preparation of an influenza virus detection test strip, and relates to the technical field of immunodetection. The detection test strip provided by the invention is composed of a sample pad, a combination pad, a nitrocellulose membrane, a water absorption pad and a bottom plate, and in the preparation process of the detection test strip, high-concentration colloidal gold with the OD value of 100 is adopted for respectively marking an influenza A virus monoclonal antibody 1, an influenza B virus monoclonal antibody 1 and a chicken IgY antibody; optimized colloidal gold labeled reconstitution fluid is mixed and then sprayed on the combination pad, and meanwhile, a corresponding capture antibody and a goat anti-chicken IgY antibody are respectively sprayed on the nitrocellulose membrane to form a detection line and a quality control line. Through the synergistic effect of the high-concentration colloidal gold mark, the optimized sample pad / combination pad treating fluid and the special sample diluent, the detection sensitivity is remarkably improved, the false negative rate is effectively reduced, and rapid, high-sensitivity and high-specificity field detection on influenza A and B viruses is realized.

The invention relates to the technical field of biology, in particular to an MDCK cell strain and application of the MDCK cell strain in preparation of influenza vaccines. The invention provides an MDCK cell strain, the preservation number of which is CCTCC NO: C202504. The cell strain not only can maintain high sensitivity and high yield to influenza viruses and ensure the yield and quality of vaccines, but also can remarkably improve the biological safety of cell matrix influenza vaccines due to elimination of tumorigenicity risk, and has a good application prospect. And a key technical support is provided for promoting domestic research and development and marketing of influenza vaccines based on cell culture.

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

The application discloses a set of molecular targets, primer compositions, methods and applications for identifying respiratory pathogens, the respiratory pathogens are novel coronavirus, influenza A virus and respiratory syncytial virus, and nucleotide sequences of the molecular targets are shown as SEQ ID NO:1-3. The application provides molecular targets, primers and probes for detecting three respiratory pathogens, and establishes a triple real-time RT-RAA detection technology, which can realize rapid identification and differentiation of three respiratory infectious disease pathogens with similar clinical symptoms within 30 minutes, reduces the operation threshold of the existing detection technology, realizes the target of rapidly, simply and accurately identifying and differentiating the three viruses, meets the needs of early clinical diagnosis of infection, provides technical support for precise medication, and has wide application value.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The invention provides a plant fiber containing a ginger extract and a preparation process of the plant fiber. After the plant fiber is washed for 50 times, the bacteriostasis rates of the plant fiber to staphylococcus aureus, escherichia coli, klebsiella pneumoniae and candida albicans are all greater than or equal to 95%, the killing rates of the plant fiber to influenza viruses H3N2 and H1N1 are all greater than or equal to 99%, the far infrared emissivity is 0.89-0.95, the highest temperature rise of moisture absorption and heating is 4-12 DEG C, and the average temperature rise is 3-8 DEG C. A vapor deposition method is adopted, a biomass component A and a biomass component B are combined to form a biomass component C, on one hand, the biomass component B serves as a tube bundle-shaped base material, rhizome plants are calcined to form a porous carbon structure framework, the porous carbon structure framework serves as a solid for vapor deposition, and a solution containing the biomass component A is small in gas molecular weight; after being vaporized along with the solution, the solution is caught by a porous structure of the biomass component B and uniformly filled into pores of the biomass component B, so that the durability of plant functions is ensured, and meanwhile, a protection effect at high temperature is achieved.

The invention discloses RT-qPCR-HRM (real-time quantitative polymerase chain reaction-high-resolution melting) detection primers and a detection method for identifying five different subtype avian influenza viruses, and belongs to the technical field of biology. The invention discloses an RT-qPCR-HRM detection method for identifying five different subtypes of avian influenza viruses, which comprises the following steps: designing a specific primer based on a highly conserved region of an AIV M gene, and simultaneously carrying out genetic typing on five subtypes of AIV strains H3, H5, H6, H7 and H9 in combination with an HRM technology; by comparing melting curve characteristics of M gene segments of different subtypes of AIV, an AIV detection method with good sensitivity and specificity is established. According to the method, the five AIVs of H3, H5, H6, H7 and H9 can be accurately typed, the defect of missing detection of a traditional AIV detection method is overcome, and the method has a wide application prospect.

The invention provides an influenza virus that demonstrates enhanced growth in Vero cells. The influenza virus includes PA, NP, and NS gene segments having selected nucleotides and encoding proteins having amino acid sequences with selected amino acids. The invention also provides a pharmaceutical formulation containing the influenza virus, as well as a method of eliciting an immune response in a mammal by administering the influenza virus to the mammal, and a method for generating the influenza virus.

The present disclosure relates to compositions and methods for treating viral infections. Compositions and methods for treating viral infections include conjugates comprising a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or an analog thereof) linked to an Fc monomer, an Fc domain, and an Fc binding peptide, albumin, or an albumin binding peptide. In particular, the conjugates are useful in the treatment of viral infections (e.g., influenza virus infections).

The application belongs to the technical field of biology and particularly relates to an ELISA kit for detecting chicken astrovirus type II antibodies and a preparation method. The Cell-ELISA experiment is carried out by using LMH cells infected with chicken astrovirus type II to detect the chicken astrovirus type II antibodies. The method has no cross reactivity with positive serum of Newcastle disease virus, avian influenza virus, chicken infectious anemia virus, avian leukosis virus, Marek's virus and chicken infectious bursal virus, which indicates that the method has good specificity. The Cell-ELISA method is used to detect the chicken serum sample to be detected by using whole virus infection, and is assembled into a kit for measuring chicken astrovirus antibodies in serum. The kit can be used for serological diagnosis of chicken astrovirus type II infection, monitoring of the level of antibodies, epidemiological investigation and the like, and provides a novel and effective detection means for prevention and treatment of chicken astrovirus type II.

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is comprised between 1.5:1 and 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and / or Influenza B.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.

The invention relates to the field of biology, and particularly provides a replication-deficient influenza virus vaccine skeleton which comprises a PA gene, an HA gene, an NP gene, an NA gene, an M gene, an NS gene and a PB2 gene of an influenza virus. The PB2 gene is replaced into a PB1 gene coding region of a vaccine skeleton; the open reading frame of the original PB2 gene can be replaced by an exogenous gene, so that the exogenous gene is inserted into the vaccine skeleton and expressed. The skeleton has the advantages that the capacity is large, the antigen can be efficiently and stably expressed, the passage is stable, and the like. Meanwhile, the invention also discloses a replication-defective influenza virus as well as a preparation method and application thereof.

The invention relates to construction and application of H7 subtype and H5 and H7 tetravalent avian influenza DNA vaccines. The invention belongs to the field of molecular biology, and aims to provide a DNA (deoxyribonucleic acid) vaccine for providing efficient immune protection for H7 subtype avian influenza virus. Specifically, the invention discloses an H7 subtype avian influenza virus hemagglutinin protein, which has an amino acid sequence as shown in SEQ ID NO: 5 and / or SEQ ID NO: 6. The invention also discloses polynucleotide for coding the protein, and the polynucleotide has a sequence as shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. The polynucleotide can be used for preparing a vaccine aiming at the current epidemic H7 subtype avian influenza virus. The H5 + H7 tetravalent DNA vaccine is obtained by combining the vaccine with a vaccine aiming at the H5 subtype, and the H5 + H7 tetravalent DNA vaccine can be used for prevention and control of current H5 subtype and H7 subtype avian influenza.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

The present disclosure relates to the field of influenza viruses. More specifically, the present disclosure relates to donor or seed influenza viruses for the preparation of reassorted influenza viruses for vaccine production.

The invention discloses a non-tumorigenic MDCK cell strain, a screening method and application. The non-tumorigenic MDCK cell strain is MDCK-CA027 (the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2023329). The tumor formation rate of the cell strain is 0% when the cell strain is observed for at least 16 weeks in a nude mouse in-vivo tumor formation test, and the cell strain has good sensitivity to various influenza viruses (such as H1N1, H3N2, BY and BV). The invention also provides a method for screening the cell strain. The method comprises the following steps: preparing a single-cell suspension, carrying out limited dilution to obtain monoclone, carrying out enlarged culture, carrying out virus sensitivity detection, carrying out in-vitro tumorigenicity related detection (clone formation test / soft agar test), carrying out nude mouse in-vivo tumorigenicity test and the like. The non-tumorigenic MDCK cell strain is high in safety, can efficiently support influenza virus replication, can be safely and effectively applied to influenza vaccine production and influenza virus amplification, overcomes the tumorigenic risk of traditional MDCK cells, and has important scientific significance and application prospects.

The present disclosure provides antibody-drug conjugates or drug-Fc conjugates for treating and / or preventing an influenza viral infection in a subject in need thereof.

Described herein is a method of treating, ameliorating, and / or preventing an influenza viral infection in a subject, and / or immunizing a subject against an influenza viral infection, which include parenterally administering to the subject a first composition including a first compound in an amount sufficient to elicit systemic T and / or B cell response(s) against a first influenza virus in the subject; and administering to the subject a second composition including a viral protein of a second influenza virus through an administration route comprising intranasal, inhalational, intratracheal, intrapulmonary, and intrabronchial, in an amount sufficient to result in establishment of tissue-resident T cell(s), tissue-resident B cell(s), mucosal IgA, and / or systemic IgG specific against the influenza viral infection in the subject. Also described are a kit for performing the method, as well as methods and kits for boosting existing immunity against influenza viral infections.

The present application discloses an anti-influenza virus pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof or a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are as defined in the specification. The present application also discloses the use of the pharmaceutical composition in the preparation of a medicament for preventing or treating influenza.